Background: The aim of the study was to investigate Programmed cell Death protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) and their mRNA expression in thymic epithelial tumors (TETs). Research design and Methods: We analyzed 68 samples of formalin-fixed paraffin embedded tissue (63 thymomas and 5 thymic carcinomas). PD-1 and PD-L1 protein expression was evaluated by immunohistochemistry and mRNA expression was evaluated by Real Time-PCR. Results: M/F ratio was 33/35, and median age was 60.5 years. 20 patients had Myasthenia Gravis (MG). In the subgroup with large tumors (>5 cm), PD-L1 mRNA overexpression was significantly associated with worse prognosis vs. patients with no mRNA overexpression (p =0.0083) and simultaneous PD-L1 immunostaining (>1%); PD-L1 mRNA overexpression was significantly associated with worse prognosis, respect to patient with PD-L1 negative immunostaining and no PD-L1 mRNA overexpression (p = 0.0178). The elderly patients (> 60 years) with large tumors showed worse prognosis (p = 0.0395). PD-L1 immunostaining (>50%) resulted significantly associated with MG. Conclusions: Our data suggest the potential involvement of the PD-1 and PD-L1 pathway in TETs progression. According to our results, it may be helpful to design future trials with anti-PD-1 drugs to establish high-risk patients after surgery.

Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach / Berardi, R.; Goteri, G.; Brunelli, A.; Pagliaretta, S.; Paolucci, V.; Caramanti, M.; Rinaldi, S.; Refai, M.; Pompili, C.; Morgese, F.; Torniai, M.; Marcantognini, G.; Ricci, G.; Mazzanti, P.; Onofri, A.; Bianchi, F.; Sabbatini, A.; Cascinu, S.. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - (2020), pp. 1-7. [10.1080/14728222.2020.1790529]

Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach

Berardi R.;Goteri G.;Pagliaretta S.;Paolucci V.;Caramanti M.;Pompili C.;Morgese F.;Torniai M.;Marcantognini G.;Ricci G.;Onofri A.;Bianchi F.;
2020-01-01

Abstract

Background: The aim of the study was to investigate Programmed cell Death protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) and their mRNA expression in thymic epithelial tumors (TETs). Research design and Methods: We analyzed 68 samples of formalin-fixed paraffin embedded tissue (63 thymomas and 5 thymic carcinomas). PD-1 and PD-L1 protein expression was evaluated by immunohistochemistry and mRNA expression was evaluated by Real Time-PCR. Results: M/F ratio was 33/35, and median age was 60.5 years. 20 patients had Myasthenia Gravis (MG). In the subgroup with large tumors (>5 cm), PD-L1 mRNA overexpression was significantly associated with worse prognosis vs. patients with no mRNA overexpression (p =0.0083) and simultaneous PD-L1 immunostaining (>1%); PD-L1 mRNA overexpression was significantly associated with worse prognosis, respect to patient with PD-L1 negative immunostaining and no PD-L1 mRNA overexpression (p = 0.0178). The elderly patients (> 60 years) with large tumors showed worse prognosis (p = 0.0395). PD-L1 immunostaining (>50%) resulted significantly associated with MG. Conclusions: Our data suggest the potential involvement of the PD-1 and PD-L1 pathway in TETs progression. According to our results, it may be helpful to design future trials with anti-PD-1 drugs to establish high-risk patients after surgery.
2020
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/283755
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact